Navigating the Dual Imperatives: Technology Adoption and Patient-Centricity in Clinical Trials

New Brunswick, New Jersey – May 15, 2026 – The landscape of clinical research is undergoing a profound transformation, driven by an accelerating push towards technological innovation. From artificial intelligence (AI) and wearable devices to sophisticated remote monitoring systems, these advancements promise greater efficiency, richer data, and broader participant reach. Yet, at the heart of every successful trial lies the patient, and experts are increasingly grappling with the critical challenge of integrating these cutting-edge tools without inadvertently creating new barriers or diluting the human element of healthcare.

n

This delicate balance formed the cornerstone of a vital discussion at the recent Outsourcing in Clinical Trials (OCT) East Coast conference, held on May 12-13, 2026, in New Brunswick, New Jersey. In a compelling podcast moderated by Manasi Vaidya, Editor, GlobalData Insights, two prominent figures in clinical research – Jonathan Kornstein, Vice President and Therapeutic Area Head, Rare Disease and Pediatrics at the Contract Research Organization (CRO) Caidya, and April Bell, Interim Director at the Office of Clinical Research at the JPS Health Network in Fort Worth, Texas – offered their perspectives on navigating this complex terrain. Their insights underscored a unanimous commitment: technology must serve the patient, not overshadow their fundamental needs and experiences.

n

The Core Dilemma: Innovate While Empathizing

n

The central tension explored by Kornstein and Bell revolves around the rapid integration of advanced technologies like AI, wearable sensors, and remote monitoring into clinical trial workflows. While these tools offer undeniable benefits – from streamlining data collection and improving monitoring frequency to potentially expanding access to trials for geographically dispersed populations – they also introduce new complexities for participants. The conversation illuminated how research stakeholders, including sponsors, CROs, and clinical sites, are striving to harness innovation while simultaneously enhancing the patient experience, ensuring that technological progress genuinely translates into improved accessibility, comfort, and meaningful support for those volunteering for studies.

n

The Evolving Landscape of Clinical Trials

n

The journey of clinical trials has been one of continuous evolution, marked by periods of incremental change punctuated by transformative shifts. Historically, clinical research was predominantly conducted in highly centralized, academic medical centers, characterized by stringent protocols, frequent in-person visits, and often a significant burden on patients who had to travel extensively and adhere to rigid schedules. The focus was primarily on scientific rigor and regulatory compliance, with patient convenience often a secondary consideration. This traditional model, while foundational to medical progress, inherently limited participation to those with the means, time, and proximity to major research hubs.

n

The past decade, however, has witnessed an accelerated push for change, particularly amplified by global health crises such as the COVID-19 pandemic. The imperative to conduct research remotely and minimize physical contact propelled the adoption of digital solutions at an unprecedented pace. This era ushered in the widespread acceptance of decentralized clinical trials (DCTs) and hybrid models, which leverage technology to reduce the need for site visits, collect data remotely, and enhance patient engagement from the comfort of their homes. This shift, while necessary, also brought to light the significant disparities in digital literacy, access to technology, and reliable internet connectivity among potential participants, posing new ethical and logistical challenges.

n

The OCT East Coast conference served as a timely forum for these discussions, gathering industry leaders to dissect the impact of these changes and chart a course forward. The event, a cornerstone for professionals involved in outsourcing clinical trial activities, provided a platform for sharing best practices, discussing regulatory shifts, and exploring innovative solutions to the sector’s most pressing challenges. It underscored that while the pursuit of scientific breakthroughs remains paramount, the methods by which these breakthroughs are achieved must increasingly prioritize the well-being and practical needs of the patients who make them possible. The dialogue between Kornstein and Bell, therefore, was not merely an academic exercise but a practical exploration of how to bridge the gap between technological aspiration and human reality in the contemporary clinical research environment.

n

Supporting Data: The Promise, Peril, and Practicalities of Modern Research

n

The integration of advanced technologies like AI, wearables, and remote monitoring is poised to revolutionize clinical trials, yet their implementation comes with a complex array of promises and perils that demand careful consideration. Understanding the underlying data and implications of these technologies is crucial for fostering truly patient-centric research.

n

The Promise and Perils of New Technologies:

n

n
• n

  Artificial Intelligence (AI): AI holds immense potential across the entire drug development lifecycle. In clinical trials, AI algorithms can accelerate patient identification and recruitment by sifting through vast datasets of electronic health records to pinpoint eligible candidates more efficiently. It can also optimize trial design, predict patient responses, and analyze complex data from wearables and other sources to identify subtle patterns that human analysis might miss. The promise is faster drug discovery, more personalized treatments, and improved trial efficiency. However, the perils are equally significant. AI models can perpetuate or even amplify biases present in their training data, leading to inequities in patient selection or treatment recommendations. Ethical concerns surrounding data privacy, algorithmic transparency, and accountability remain paramount. Furthermore, the "digital divide" means that relying solely on AI-driven recruitment could exclude populations with limited access to digital health records or internet connectivity, exacerbating health disparities.

  n

n

• n

  Wearables & Remote Monitoring: Wearable devices (like smartwatches, continuous glucose monitors, and activity trackers) and remote monitoring tools (such as ePROs/eCOAs, telehealth platforms) offer a wealth of benefits. They enable real-time, continuous data collection, providing a richer, more granular understanding of a patient’s health status and response to treatment outside of sporadic clinic visits. This can reduce the burden on patients by minimizing travel to sites, improve data accuracy by capturing information in real-world settings, and expand geographical reach for trials. For rare diseases, where patient populations are small and widely dispersed, these technologies are particularly transformative. Yet, challenges persist. The cost of devices, ensuring data security and privacy, managing the sheer volume of data generated, and ensuring patient compliance with technology use are significant hurdles. Technical literacy and reliable internet access are prerequisites, which can exclude vulnerable populations. Data overload for sites and the need for robust infrastructure to manage and interpret this data are also critical considerations.

  n

n

• n

  Decentralized Clinical Trials (DCTs): DCTs, which leverage many of these technologies, represent a paradigm shift. By allowing participants to engage from home or local community settings, DCTs significantly enhance convenience and accessibility, potentially boosting recruitment and retention rates, especially for those with mobility issues, demanding jobs, or childcare responsibilities. However, DCTs introduce their own set of complexities. Regulatory frameworks are still adapting to these models, and ensuring consistent quality and oversight across diverse remote settings can be challenging. Integrating disparate technologies, ensuring data interoperability, and maintaining robust patient engagement without in-person interactions require careful planning and execution. The risk of exacerbating the digital divide is particularly high in DCTs, requiring proactive strategies to provide necessary equipment, internet access, and technical support.

  n

n

n

The Economic and Human Cost of Patient Dropout:

n

Poor patient recruitment and retention are among the most significant bottlenecks in clinical research, incurring substantial economic and human costs. Industry estimates suggest that up to 80% of clinical trials fail to meet their recruitment timelines, leading to delays that can cost drug developers millions of dollars per day. Furthermore, dropout rates, which can range from 15% to 40% depending on the therapeutic area and trial duration, further erode data integrity and prolong development timelines. Beyond the financial implications, patient dropout represents a profound human cost: delayed access to potentially life-saving treatments, wasted resources, and the unfulfilled promise to patients who dedicated their time and hope to research. Understanding and addressing the root causes of dropout – often logistical, financial, or emotional burdens – is therefore not just good practice, but an ethical imperative.

n

The Imperative for Real-World Support:

n

April Bell’s poignant statement, "We don’t need advertising dollars… we need to be able to help these people live… with food and housing," encapsulates a critical, often overlooked dimension of patient-centricity. Many potential trial participants face significant socio-economic barriers that transcend the medical aspects of their condition. These can include:

n

n
• Transportation: The cost and logistics of traveling to study sites, especially for frequent visits or those in rural areas.

n

• Childcare/Elderly Care: The inability to participate due to responsibilities for dependents.

n

• Lost Wages: The financial impact of taking time off work for appointments.
• Food Insecurity and Housing Instability: Basic needs that, if unmet, make participation in a trial an insurmountable challenge.
• Digital Literacy and Access: The inability to engage with technology-driven trials due to lack of skills, devices, or reliable internet.

Addressing these fundamental needs through practical, real-world support – such as providing transport vouchers, childcare stipends, flexible scheduling, or direct assistance for food and housing – can have a more profound impact on enrollment and retention than sophisticated technological solutions alone. It acknowledges the holistic reality of a patient’s life and demonstrates genuine empathy, transforming the trial experience from a burden into a manageable and even supportive journey.

Regulatory Frameworks and Their Influence:

Changes in federal laws and within agencies like the US Department of Health and Human Services (HHS) profoundly shape the conduct of clinical research. Regulators like the FDA are continually working to adapt guidelines to accommodate new technologies, such as DCTs and AI-driven tools, while maintaining patient safety, data integrity, and ethical standards. Policy shifts at HHS, which oversees numerous health initiatives and research funding, can impact everything from data sharing requirements to funding priorities for specific disease areas. Staying abreast of these evolving regulatory landscapes is crucial for CROs and sites to ensure compliance, foster innovation responsibly, and advocate for policies that support both technological advancement and patient welfare. The interplay between regulatory bodies and industry stakeholders is a dynamic one, constantly striving to strike a balance between accelerating medical progress and safeguarding human subjects.

Official Responses: Architects of Patient-Centric Innovation

The insights shared by Jonathan Kornstein and April Bell are not mere observations but active strategies being implemented within their respective organizations. Their "official responses" demonstrate a proactive approach to embedding patient-centricity within the technological revolution of clinical trials.

Prioritizing the Patient Journey at Caidya:

Jonathan Kornstein, speaking from the perspective of a leading CRO, highlighted Caidya’s deep commitment to understanding the patient experience from the outset. "I’m a big proponent of taking the patient-centric approach… We [at Caidya] think about the patient journey before we start." This isn’t just a mission statement; it translates into tangible operational practices. Kornstein explained that this involves comprehensive pre-trial planning where patient perspectives are actively sought and integrated. This can manifest through:

• Patient Advisory Boards: Engaging actual patients and caregivers early in the trial design process to gather feedback on protocols, consent forms, visit schedules, and technology interfaces. This ensures that the trial design is truly feasible and acceptable from a patient’s viewpoint.
• Empathy Mapping: A structured approach to understanding a patient’s emotional, physical, and logistical experiences throughout a potential trial. This helps identify pain points and opportunities for support.
• Tailored Recruitment Strategies: Moving beyond traditional advertising to engage patient advocacy groups, community leaders, and local healthcare providers who understand the specific needs of diverse patient populations.
• Flexible Protocol Design: Designing protocols with patient burden in mind, for instance, by optimizing the number and timing of visits, considering the overall duration of the trial, and minimizing invasive procedures.

By front-loading this patient-centric thinking, Caidya aims to create trials that are not only scientifically robust but also inherently appealing and manageable for participants. Kornstein noted that this approach significantly improves recruitment and retention rates, leading to higher patient satisfaction and, ultimately, more successful trials. When patients feel valued and understood, they are more likely to complete the study and even advocate for research participation within their communities.

Addressing Fundamental Needs at JPS Health Network:

April Bell’s insights from the JPS Health Network, a public health system, powerfully underscore the reality that for many patients, the most sophisticated technologies are secondary to basic human needs. Her statement, "We don’t need advertising dollars… we need to be able to help these people live… with food and housing," is a direct call to action for sites and sponsors to recognize and address the social determinants of health that impact trial participation. At JPS, this translates into practical, immediate interventions:

• Holistic Patient Assessment: Beyond medical eligibility, JPS staff assess patients for non-medical barriers to participation, such as transportation challenges, food insecurity, or lack of childcare.
• Direct Support Programs: Implementing programs that provide tangible aid, such as transportation vouchers, gas cards, or arranging ride-sharing services for clinic visits. For patients struggling with food insecurity, connections to local food banks or direct provision of healthy meals during site visits can be crucial.
• Community Partnerships: Collaborating with local social services, community centers, and non-profits to create a network of support for trial participants. This extends the site’s ability to assist beyond its immediate medical capacity.
• Flexible Scheduling and Communication: Offering flexible appointment times, clear and culturally sensitive communication, and dedicated patient navigators to help participants manage their trial commitments alongside their daily lives.

Bell emphasized that by "meeting the patient where they are" and actively checking on their needs, sites can dramatically improve their ability to not only enroll but also retain patients. This human-first approach builds trust and rapport, making patients feel genuinely cared for rather than just being a data point in a study.

The Role of Decentralization and Technology in Patient Burden Reduction:

Kornstein further elaborated on how Caidya integrates technology to reduce patient burden, specifically mentioning decentralized approaches where applicable, such as with electronic Clinical Outcome Assessments (eCOAs) and home nursing solutions.

• eCOAs (electronic Clinical Outcome Assessments): These digital tools allow patients to report their symptoms, quality of life, and other outcome measures directly from their homes using smartphones or tablets. This eliminates the need for frequent site visits solely for data collection, providing more accurate, real-time data while significantly enhancing patient convenience.
• Home Nursing Solutions: For trials requiring blood draws, physical assessments, or drug administration, home nursing services bring the clinical trial directly to the patient’s residence. This is particularly beneficial for elderly, immunocompromised, or mobility-impaired patients, drastically reducing their travel burden and exposure risks.

These technological implementations, when combined with foundational patient support, embody a comprehensive strategy that respects both the scientific rigor of research and the lived realities of participants. It’s about smart technology adoption that genuinely serves to lighten the load on patients and their caregivers, making clinical trials more accessible and sustainable for a wider demographic.

Collaboration Between CROs and Sites:

The dialogue implicitly highlighted the critical collaboration required between CROs like Caidya and clinical sites like JPS Health Network. CROs, with their global reach and expertise in trial design and management, can develop patient-centric protocols and technology solutions. Sites, on the front lines of patient care, provide invaluable insights into the practical challenges faced by real-world patients and are responsible for implementing the patient support mechanisms. This symbiotic relationship is essential for translating patient-centric philosophy into effective, equitable clinical trial execution.

Implications: Shaping the Future of Clinical Research

The discussions at OCT East Coast, particularly the insights from Jonathan Kornstein and April Bell, carry significant implications for the future trajectory of clinical research. They underscore a paradigm shift where technological advancement must be inextricably linked with profound human empathy and practical support.

The Future of Clinical Trials: A Hybrid and Equitable Model:

The prevailing consensus points towards a future dominated by hybrid clinical trial models. This means a strategic blend of traditional site-based visits for critical procedures with decentralized components utilizing AI, wearables, and remote monitoring for data collection, follow-ups, and patient engagement. This hybrid approach aims to maximize flexibility and accessibility without compromising data integrity or patient safety. Crucially, the move towards decentralization must be accompanied by a robust commitment to digital equity. This means proactively addressing the digital divide by providing necessary devices, internet access, and technical support to all participants, ensuring that technology does not inadvertently exclude vulnerable populations. The goal is to create trials that are accessible to anyone, regardless of their socio-economic status or technological proficiency.

Impact on Drug Development: Faster, More Efficient, and Patient-Aligned:

When patients are genuinely prioritized and supported, the ripple effects throughout the drug development pipeline are substantial. Improved recruitment and retention rates translate directly into faster trial completion times, bringing potentially life-saving therapies to market more quickly. Enhanced patient engagement leads to higher quality, more complete data, which strengthens the scientific validity of trial results. Furthermore, incorporating patient perspectives from the outset ensures that the treatments being developed truly address the needs and preferences of those who will ultimately use them. This patient-aligned approach not only accelerates development but also increases the likelihood of successful market adoption for new drugs, creating a virtuous cycle of innovation and patient benefit.

Ethical Considerations: Beyond Data Privacy:

While data privacy and security remain paramount concerns with the rise of digital technologies, the ethical implications extend further. The industry must grapple with questions of algorithmic bias in AI-driven patient selection, ensuring that new technologies do not inadvertently exacerbate existing health disparities. There’s an ethical imperative to ensure that the convenience offered by DCTs does not lead to a reduction in personalized care or human connection. Furthermore, providing comprehensive real-world support, as advocated by Bell, becomes an ethical obligation, acknowledging that participation in research should not impose undue financial or logistical burdens on individuals already facing health challenges. Ethical frameworks must evolve to encompass the holistic well-being of the patient in an increasingly technologically advanced research environment.

Call to Action for All Stakeholders:

• Sponsors and CROs: Must embed patient-centricity into their core strategies, investing in robust patient advisory boards, developing flexible protocols, and allocating resources for direct patient support (transport, childcare, stipends). They should also prioritize equitable access to technology and digital literacy programs.
• Clinical Sites: Are crucial in implementing these patient-centric strategies on the ground. They need training, resources, and autonomy to identify and address the unique needs of their patient populations, fostering strong community ties and offering practical assistance.
• Regulators: Must continue to adapt guidelines to facilitate responsible innovation, providing clear pathways for the use of new technologies while safeguarding patient rights, data integrity, and equitable access. There’s a need for ongoing dialogue between regulators and industry to ensure that policies are both protective and progressive.
• Technology Providers: Have a responsibility to design user-friendly, secure, and interoperable platforms that genuinely reduce patient burden and enhance the research experience, rather than adding complexity.

The Ultimate Goal:

Ultimately, the goal of this complex dance between technology and patient-centricity is singular: to advance medical science in a way that is respectful, equitable, and ultimately beneficial to humanity. By embracing innovation with an unwavering commitment to the patient experience, the clinical research community can forge a future where groundbreaking treatments are developed faster, more efficiently, and reach every individual who needs them, ensuring that no patient is left behind in the pursuit of scientific progress. The insights from the OCT East Coast conference serve as a powerful reminder that while technology paves new paths, it is human empathy that lights the way.